June 25, 2026- Dr. Lili Yang receives a $7.49 million CIRM Preclinical Development Award to bring a novel stem cell-engineered off-the-shelf CAR-NKT cell therapy for multiple sclerosis (a CNS autoimmune disease) into clinics. [Link][PDF] May 30, 2024- Dr. Lili Yang […]
June 16, 2026- Our Postdoctoral Scholar, Dr. Yan-Ruide (Charlie) Li, receives a California Breast Cancer Research Program (CBCRP) Fellowship. Congratulations! [California Breast Cancer Research Program] June 8, 2026- Dr. Lili Yang and our Postdoctoral Scholar, Dr. Yan-Ruide (Charlie) Li, both […]
June 11, 2026- Our research article is published on Research, reporting universal rejuvenated hematopoietic stem and progenitor cell-engineered CAR-armored natural killer T cells for malignant pleural mesothelioma. Congratulations to all the authors, in particular to the co-first authors, Yan-Ruide (Charlie) […]
We are currently recruiting PhD students (2 openings) and postdoctoral researchers (1 opening). Welcome to apply! [PhD Openings][Postdoc Openings]
May 11, 2021- Our off-the-shelf cell therapy technology is licensed by a Biotech startup, Appia Bio, for commercial development. The company launches with $52 million Series A financing. [Appia News][Endpoints News] August 5, 2021- Appia Bio and Kite announce collaboration […]
